Opko Health (OPK) is Initiated by Standpoint Research to Buy, Price Target at $16

Opko Health (OPK) was Initiated by Standpoint Research to “Buy” and the brokerage firm has set the Price Target at $16. Standpoint Research advised their investors in a research report released on Jun 3, 2016.

Many Wall Street Analysts have commented on Opko Health. Shares were Reiterated by Barrington Research on Mar 31, 2016 to “Outperform” and Lowered the Price Target to $ 16 from a previous price target of $17 .

On the company’s financial health, Opko Health reported $-0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on May 9, 2016. Analyst had a consensus of $-0.03. The company had revenue of $291.00 million for the quarter, compared to analysts expectations of $266.30 million. The company’s revenue was up 866.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.

Opko Health closed down -0.1 points or -0.94% at $10.53 with 16,82,780 shares getting traded on Wednesday. Post opening the session at $10.53, the shares hit an intraday low of $10.37 and an intraday high of $10.59 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Jun 2, 2016, Gamma Investments Trust Frost (CEO) purchased 10,800 shares at $10.50 per share price. According to the SEC, on May 17, 2016, Robert A Baron (director) sold 37,500 shares at $9.83 per share price. On Mar 18, 2016, Jane Ph D Hsiao (Vice Chairman & CTO) purchased 1,200 shares at $10.65 per share price, according to the Form-4 filing with the securities and exchange commission.

OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.

Opko Health

Leave a Reply

Opko Health - Is it time to Sell?

Top Brokerage Firms are advising their investors on Opko Health. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.